The big news yesterday was important additional information about the new cholesterol lowering PCSK9 inhibitors from Amgen AMGN +5.69% and Sanofi /Regeneron. As I reported then, the studies were broadly consistent, showing the powerful cholesterol-lowering effects of the drugs and providing an early suggestion that the drugs may lead to significant reductions in heart attacks, stroke, and other cardiovascular events. But one finding, though not entirely new, has prompted a lot of discussion and concern.
Hey, check out all the research scientist jobs. Post your resume today!
